{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T08:24:55Z","timestamp":1793953495465,"version":"4.8.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000297","name":"FRAXA Research Foundation Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000297","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.pnpbp.2026.111681","type":"journal-article","created":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T22:58:08Z","timestamp":1774220288000},"page":"111681","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The selective 5-HT1A receptor biased agonist, NLX-101, corrects anomalous behavioral phenotype in a mouse model of fragile X syndrome"],"prefix":"10.1016","volume":"146","author":[{"given":"Ronan","family":"Depoort\u00e8re","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Tranfaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Newman-Tancredi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.pnpbp.2026.111681_bb0005","doi-asserted-by":"crossref","first-page":"4599","DOI":"10.1038\/s41380-022-01789-z","article-title":"Neural serotonergic circuits for controlling long-term voluntary alcohol consumption in mice","volume":"27","author":"Belmer","year":"2022","journal-title":"Mol. Psychiatry"},{"issue":"3","key":"10.1016\/j.pnpbp.2026.111681_bb0010","doi-asserted-by":"crossref","DOI":"10.3390\/ph15030337","article-title":"Molecular signaling mechanisms for the antidepressant effects of NLX-101, a selective cortical 5-HT1A receptor biased agonist","volume":"15","author":"Cabanu","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"issue":"3","key":"10.1016\/j.pnpbp.2026.111681_bb0020","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1038\/nprot.2006.170","article-title":"Assessing nest building in mice","volume":"1","author":"Deacon","year":"2006","journal-title":"Nat. Protoc."},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111681_bb0025","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s12017-015-8341-2","article-title":"NNZ-2566, a novel analog of (1-3) IGF-1, as a potential therapeutic agent for fragile X syndrome","volume":"17","author":"Deacon","year":"2015","journal-title":"Neuromolecular Med."},{"issue":"4","key":"10.1016\/j.pnpbp.2026.111681_bb0030","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/hmg\/11.4.371","article-title":"Premutation and intermediate-size FMR1 alleles in 10572 males from the general population: loss of an AGG interruption is a late event in the generation of fragile X syndrome alleles","volume":"11","author":"Dombrowski","year":"2002","journal-title":"Hum. Mol. Genet."},{"issue":"10","key":"10.1016\/j.pnpbp.2026.111681_bb0035","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1002\/aur.1814","article-title":"Behavioral abnormalities in the Fmr1-KO2 mouse model of fragile X syndrome: the relevance of early life phases","volume":"10","author":"Gaudissard","year":"2017","journal-title":"Autism Res."},{"issue":"8","key":"10.1016\/j.pnpbp.2026.111681_bb0040","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/DBP.0000000000000334","article-title":"A randomized, double-blind, placebo-controlled trial of low-dose sertraline in young children with fragile X syndrome","volume":"37","author":"Greiss Hess","year":"2016","journal-title":"J. Dev. Behav. Pediatr."},{"key":"10.1016\/j.pnpbp.2026.111681_bb0045","series-title":"Outcomes in Neurodevelopmental and Genetic Disorders","first-page":"198","article-title":"Fragile X Syndrome","author":"Hagerman","year":"2002"},{"issue":"3","key":"10.1016\/j.pnpbp.2026.111681_bb0050","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.nbd.2005.08.019","article-title":"The generation of a conditional Fmr1 knock out mouse model to study Fmrp function in vivo","volume":"21","author":"Mientjes","year":"2006","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.pnpbp.2026.111681_bb0055","doi-asserted-by":"crossref","first-page":"117989","DOI":"10.1016\/j.biopha.2025.117989","article-title":"Rescue of respiratory and cognitive impairments in Rett syndrome mice using NLX-101, a selective 5-HT1A receptor biased agonist","volume":"186","author":"Monteiro-Fernandes","year":"2025","journal-title":"Biomed. Pharmacother."},{"issue":"5","key":"10.1016\/j.pnpbp.2026.111681_bb0060","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1601-1848.2004.00076.x","article-title":"Sociability and preference for social novelty in five inbred strains: an approach to assess autistic-like behavior in mice","volume":"3","author":"Moy","year":"2004","journal-title":"Genes Brain Behav."},{"key":"10.1016\/j.pnpbp.2026.111681_bb0065","article-title":"Nest building behavior as an early indicator of behavioral deficits in mice","volume":"152","author":"Neely","year":"2019","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.pnpbp.2026.111681_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107937","article-title":"Translating biased agonists from molecules to medications: serotonin 5-HT1A receptor functional selectivity for CNS disorders","volume":"229","author":"Newman-Tancredi","year":"2022","journal-title":"Pharmacol. Ther."},{"issue":"7","key":"10.1016\/j.pnpbp.2026.111681_bb0075","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1177\/02698811241254832","article-title":"The 5-HT1A receptor biased agonists, NLX-204 and NLX-101, like ketamine, elicit rapid-acting antidepressant activity in the rat chronic mild stress model via cortical mechanisms","volume":"38","author":"Papp","year":"2024","journal-title":"J. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.pnpbp.2026.111681_bb0080","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23041935","article-title":"Fragile X syndrome: from molecular aspect to clinical treatment","volume":"23","author":"Protic","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.pnpbp.2026.111681_bb0085","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41583-021-00432-0","article-title":"The molecular biology of FMRP: new insights into fragile X syndrome","volume":"22","author":"Richter","year":"2021","journal-title":"Nat. Rev. Neurosci."},{"issue":"5","key":"10.1016\/j.pnpbp.2026.111681_bb0090","first-page":"1006","article-title":"Prevalence of carriers of premutation-size alleles of the FMRI gene--and implications for the population genetics of the fragile X syndrome","volume":"57","author":"Rousseau","year":"1995","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.pnpbp.2026.111681_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2023.109774","article-title":"Altered brain serotonin 5-HT(1A) receptor expression and function in juvenile Fmr1 knockout mice","volume":"245","author":"Saraf","year":"2024","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.pnpbp.2026.111681_bb0100","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s00213-013-3164-z","article-title":"Aggression-reducing effects of F15599, a novel selective 5-HT1A receptor agonist, after microinjection into the ventral orbital prefrontal cortex, but not in infralimbic cortex in male mice","volume":"230","author":"Stein","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pnpbp.2026.111681_bb0105","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.neuroscience.2022.11.014","article-title":"Acute and repeated administration of NLX-101, a selective serotonin-1A receptor biased agonist, reduces Audiogenic seizures in developing Fmr1 knockout mice","volume":"509","author":"Tao","year":"2023","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111681_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s11689-024-09587-0","article-title":"Acute administration of NLX-101, a serotonin 1A receptor agonist, improves auditory temporal processing during development in a mouse model of fragile X syndrome","volume":"17","author":"Tao","year":"2025","journal-title":"J. Neurodev. Disord."},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111681_bb0015","first-page":"23","article-title":"Fmr1 knockout mice: a model to study fragile X mental retardation","volume":"78","author":"The Dutch-Belgian Fragile X Consortium","year":"1994","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.pnpbp.2026.111681_bb0115","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1159\/000329421","article-title":"The psychiatric presentation of fragile x: evolution of the diagnosis and treatment of the psychiatric comorbidities of fragile X syndrome","volume":"33","author":"Tranfaglia","year":"2011","journal-title":"Dev. Neurosci."},{"key":"10.1016\/j.pnpbp.2026.111681_bb0120","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.neuropharm.2018.05.004","article-title":"Repurposing available drugs for neurodevelopmental disorders: the fragile X experience","volume":"147","author":"Tranfaglia","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pnpbp.2026.111681_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2024.110132","article-title":"Rapid reorganization of serotonin projections and antidepressant response to 5-HT1A-biased agonist NLX-101 in fluoxetine-resistant cF1ko mice","author":"Vahid-Ansari","year":"2024","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pnpbp.2026.111681_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcn.2022.103719","article-title":"Biased 5-HT1A receptor agonists F13714 and NLX-101 differentially affect pattern separation and neuronal plasticity in rats after acute and chronic treatment","volume":"120","author":"van Hagen","year":"2022","journal-title":"Mol. Cell. Neurosci."},{"issue":"16","key":"10.1016\/j.pnpbp.2026.111681_bb0135","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25168787","article-title":"Activation of the 5-HT1A receptor by Eltoprazine restores mitochondrial and motor deficits in a Drosophila model of fragile X syndrome","volume":"25","author":"Vannelli","year":"2024","journal-title":"Int. J. Mol. Sci."}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584626000771?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584626000771?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T07:34:10Z","timestamp":1793950450000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584626000771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":27,"alternative-id":["S0278584626000771"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2026.111681","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.09.16.676519","asserted-by":"object"}]},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The selective 5-HT1A receptor biased agonist, NLX-101, corrects anomalous behavioral phenotype in a mouse model of fragile X syndrome","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2026.111681","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"111681"}}